Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To produce better cell therapies, we use human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. We can direct and determine the fate of our clonal master iPSC lines to produce well-defined and uniformly composed NK- and T-cell products.
Clonal master iPSC lines can be used as a renewable source for repeatedly and cost effectively manufacturing cell therapy products that can be delivered off-the-shelf to treat many patients. Our cells of interest are the cells of the immune system. And our cell therapy product candidate pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates, that target a broad range of liquid and solid tumors.